FINNENCE ▪ THE WIRE FILE
THE WIRE · № 78548
News■ Unclear/unknown
Another Paragon spinout goes public through reverse merger
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A biotech reverse merger adds a small listing but reveals little about sector fundamentals.
Small biotech listing, limited market read-through
CATALYST TO WATCH
Trial data or financing after listing
MAIN RISK
Microcap listings often see thin liquidity
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
AFFECTEDiShares Biotech ETF · IBB
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Osara Health and Medibank partner to bring one-on-one cancer coaching to members2026-10-13 21:11 UTC
Osara Health and Medibank partner to bring one-on-one cancer coaching to members2026-10-13 21:11 UTC
←CORRELATIONshares Healthcare
FTC Seeks Sanctions Against Shkreli Over Alleged Pharma Ban Breaches2026-10-13 18:42 UTC
FTC Seeks Sanctions Against Shkreli Over Alleged Pharma Ban Breaches2026-10-13 18:42 UTC
←CORRELATIONshares Healthcare
AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease2026-10-13 19:15 UTC
AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease2026-10-13 19:15 UTC
←CORRELATIONshares Healthcare
Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)2026-10-13 19:36 UTC
Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)2026-10-13 19:36 UTC
←CORRELATIONshares Healthcare
Alaunos lands Paragon-built pulmonary hypertension pipeline via Velaris merger2026-10-13 19:36 UTC
Alaunos lands Paragon-built pulmonary hypertension pipeline via Velaris merger2026-10-13 19:36 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.